BridgeBio presents plans for three potential US drug launches by mid-2027
BBIO•BridgeBio said it has $1.5 billion in cash, cash equivalents and marketable securities to support three potential US launches by mid-2027. Attruby generated $253.2 million in third-quarter 2026 US net product revenue, and the company said potential peak sales could exceed $4 billion.
1. Launch plans and dates
BridgeBio plans US launches upon approval for BBP-418 for LGMD2I/R9, infigratinib for achondroplasia and encaleret for autosomal dominant hypocalcemia type 1. The FDA decision dates are November 27, 2026, for BBP-418; February 4, 2027, for infigratinib; and May 8, 2027, for encaleret.
2. Cash and Attruby sales
BridgeBio reported $1.5 billion in cash, cash equivalents and marketable securities. Attruby generated $253.2 million in third-quarter 2026 US net product revenue, with potential peak sales exceeding $4 billion.
